ABL1 and intrahepatic cholangiocarcinoma: Conversely, AML is defined by ICC as “at least 10% blasts in the bone marrow or peripheral blood with recurrent genetic abnormalities (with the exception of ≥ 20% in AML with BCR::ABL1)." Additionally, ICC announced a new category of MDS/AML with 10%–19% blasts in the bone marrow or peripheral blood.